Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-436-9
CAS number: 95-63-6
The acute oral and dermal LD50 values for 1,2,4-trimethylbenzene are concluded to be greater than 3000 mg/kg. In acute inhalation studies the LC50 is reported as 18,000 mg/m3. In human volunteer studies no effects were reported at concentrations up to 150 mg/m3.
a key study (MB Research Laboratories Inc, 1980) rats were given single
oral doses of from 3000-10,000 mg/kg body weight of 1,2,4
–trimethylbenzene (pseudocumene). Lethargy and ptosis were seen at all
four dose levels while ataxia and piloerection were only seen at the
three highest levels. The LD50 in this study was 6000 mg/kg. This result
is supported by the studies of Litton
Bionetics Inc (1976) where the LD50s for male and female rats were 3550
and 3280 mg/kg respectively and Lewis (2003) where oral LD50 values of
greater than 5000 mg/kg have been reported in rats. The oral toxicity of
1,2,4 –trimethylbenzene is similar to that the other trimethylbenzene
isomers in comparative studies on the isomers (Lewis, 2003) and studies
on isomer mixtures (Shellsol A -a mixture of trimethylbenzenes CAS#
64742-95-6) where an acute oral LD50 of greater than 8 mL/kg bw ( 6880
mg/kg) and approximately 4 mL/kg bw (3440 mg/kg) were reported for male
and female rats respectively (Shell
Toxicology Laboratory, 1977).
conclusion, the oral LD50 of 1,2,4-trimethylbenzene in rats is greater
than 3000 mg/kg
from robust studies on the inhalational acute toxicity of 1,2,4
–trimethylbenzene is lacking. An LC50 value of 18,000 mg/m3 in rats has
been reported for 1,2,4-TMB (Lewis, 2003), although details of the
original studies are lacking. Further details are given in the review of
Firth et al (2008). As this is not a primary reference (Klimisch 4) it
has not been designated as a key study although the LC50 below 20,000
mg/m3 leads to classification under DSD and CLP as harmful by inhalation.
adequate, key study is provided by Shell Toxicology Laboratory (1977).
Rats were exposed for 4 hours to Shellsol A (a mixture of
trimethylbenzenes CAS# 64742-95-6) at 10,200 mg/m3. There were no deaths
and no adverse signs other than lethargic behaviour. The acute LC50 was
greater than 10,200 mg/m3. This result is supported by Cameron et al
a 12 hour LD50 was greater than 9833 mg/m3 in rats and mice. Korsak and
Rydzynski (1996) tested rotarod performance and pain sensitivity
behaviour in rats exposed to 1,2,4 –trimethylbenzene for 4 hours.
Disturbances in rotarod performance and decreased pain sensitivity
occurred with EC50 values for rotarod performance being 4690 mg/m3 and
for pain sensitivity being 5679 mg/m3. Korsak et al (1997) investigated
the effect of 1,2,4 –trimethylbenzene on
respiratory sensory irritation in male mice after acute exposure to 2842
mg/m3 but this study is described in the “Irritation Section”. The
inhalational toxicity of 1,2,4 –trimethylbenzene is also similar to that
the other trimethylbenzene isomers in comparative studies on the isomers
(Lewis, 2003, Korsak et al 1997)
conclusion, the available data indicates that 1,2,4-trimethylbenzene has
low acute inhalational toxicity at exposures up to approximately 10,200
mg/m3. However, the secondary reference of Lewis indicates an LC50 in
rats below 20,000 mg/m3.
information is available for the acute toxicity of 1,2,4-
trimethylbenzene by dermal application. One dermal acute study showed an
LD50 value of greater than 3440 mg/kg after exposure of rats to Shellsol
A (a mixture of trimethylbenzenes CAS# 64742-95-6) for 24 hours (Shell
Toxicology Laboratory, 1977). A poorly reported study (IUCLID 4 record)
in guinea pigs indicated that there were no deaths when guinea pigs were
exposed to 1,2,4 -trimethylbenzene (Solvesso 100) at approximately 890
and 1695 mg/kg by dermal application (ESBI 1975)
is no information available on the effects of trimethylbenzenes in
humans after oral and dermal exposure. Information on the effects of
inhaled 1,2,4-trimethylbenzene is available from human volunteer
toxicokinetics studies and indicates no signs of toxicity for exposures
up to 150 mg/m3. Jarnberg et al (1996) assessed the toxicokinetics of
inhaled trimethylbenzenes in man. Ten
male volunteers were exposed to 120 mg/m3 of 1,2,4-TMB for 2 hours in an
exposure chamber at a constant work load of 50 W on an ergometer bicycle. Before,
during and after exposure the subjects rated symptoms related to
irritation or the central nervous system from "no effect at all" to
"almost unbearable" for (i)
Discomfort in eyes: burning, irritation, or running eyes; (ii)
discomfort in nose: burning, irritation, or running nose; (iii)
discomfort in throat or airways; (iv) headache; (v) fatigue; (vi)
nausea; (vii) dizziness; (viii) intoxication; (ix) difficulty in
breathing and (x) smell of solvent. No effects were reported.
Kostrzewski et al (1997) also exposed human volunteers to up to 150
mg/m3 for 4 or 8 hours. Clinical examinations (internal, laryngologic,
neurologic and haematologic) were carried out before the onset of
exposure, after exposure and repeatedly after the experiment at 3 month
intervals but no abnormalities were detected.
via the oral and inhalational routes are the most relevant for
1,2,4-trimethylbenzene. Data in rats indicate a low potential for acute
oral toxicity with the oral LD50 of 1,2,4-trimethylbenzene in rats being greater
than 3000 mg/kg. Inhalational exposure of humans up to 150 mg/m3
resulted in no acute toxicity but the
LC50 in rats of 18,000 mg/m3 results in its being classified as harmful
classification for acute oral or dermal toxicity is warranted under DSD
or CLP. 1,2,4 -Trimethylbenzene is classified as harmful by inhalation
under DSD (Xn, R20) and this is equivalent to a classification of Acute
Tox Category 4, H332: Harmful if inhaled, under CLP.
kinematic viscosity of 1,2,4 -trimethylbenzene justifies classification
Xn, R65, under DSD and, under CLP, Aspiration Tox Category 1, H304
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again